WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 2674

Legislative bill overview

SB 2674 requires health benefit plans in Texas to cover certain biomarker testing for patients. The bill specifies which types of biomarker tests must be included in insurance coverage, though specific testing types are not detailed in the available bill information. This legislation aims to ensure broader access to diagnostic testing that identifies biological markers associated with disease risk or treatment response.

Why is this important

Biomarker testing can guide treatment decisions, improve patient outcomes, and potentially reduce unnecessary procedures by identifying which patients will benefit from specific therapies. However, insurance coverage gaps for these tests can create barriers to early detection and precision medicine, particularly for lower-income patients. This bill addresses accessibility concerns by mandating coverage requirements.

Potential points of contention

  • Cost implications: Requiring coverage of biomarker testing increases insurance costs, which may be passed to employers and consumers through higher premiums
  • Which tests qualify: Disputes may arise over which specific biomarker tests insurers must cover, and whether the definition is broad enough or too expansive
  • Medical necessity standards: Disagreement between insurers and providers over whether certain biomarker tests meet evidence-based medical necessity criteria for coverage

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.